Tuesday 10 November 2020

The Brewery, London EC1

2013 Voting Panel


Mette Kristine Agger

Lundbeckfond Ventures

Mette is Managing Partner in Lundbeckfond Ventures, an evergreen life science venture und. Mette has more than 20 years of broad international experience within biotech/life science covering business development and licensing, management and financing. She was previously co-founder and CEO of 7TM Pharma. Prior to that she was part of the management team of NeuroSearch A/S responsible for business development and licensing and has over the years co-founded several biotech companies. She started her career as Patent Agent. Mette has been appointed to numerous board positions both in private and public companies. Mette graduated with a degree in Biology from the University of Copenhagen and has an MBA.



Amber Bielecka


Amber joined the M:Communications Healthcare team in 2010, assisting the team in establishing itself as the sector's leading financial and corporate communications agency. Amber has extensive experience of providing strategic communications support to some of the healthcare sector's leading companies and has delivered successful PR campaigns, including significant sector IPOs, M&A and public and private fundraisings, across Europe and North America.

Amber joined M:Communications from Citigate Dewe Rogerson and has a strong background in public affairs and lobbying.


 Mark Court.jpg

Mark Court


At Buchanan, Mark advises a wide range of healthcare clients on their communication requirements. He joined Buchanan in 2003 after a successful career in journalism on titles including The Times, where he was Health Industries Correspondent, the Sunday Telegraph, Daily Mail and Investors Chronicle. A science graduate of London University, Mark also holds a diploma from the London College of Communication.


Glyn Edwards

Summit plc

Glyn is CEO of Summit plc, a drug discovery and development company advancing innovative therapies to treat areas of high unmet medical need. He was previously Chief Executive Officer of Antisoma from 1998 to 2011 and prior to this he worked in a variety of business development roles in the biotech and healthcare industries. Glyn has a BSc in Biochemistry from Bristol University and an MSc in Economics from the London Business School. Glyn was made a Member of the British Empire as recognition for his services to the biotechnology industry.



Stefan Hamill

Peel Hunt

Stefan joined Peel Hunt in January 2011, joining forces with Paul Cuddon to form what Peel Hunt believes is the strongest team in UK healthcare and life sciences. Prior to joining Peel Hunt, Stefan was a founder of independent research house Clear Capital (now part of Espirito Santo) where he covered a wide variety of firms across the sector and was ranked No. 3 in Extel. Stefan was formerly a strategy consultant and has a PhD in Antibody Engineering from the University of Cambridge.


Oscar Izeboud

Kempen & Co

Oscar joined Kempen & Co, a merchant bank based in Amsterdam, in 2006. He is currently Managing Director Corporate Finance, heading the Life Sciences/ Healthcare team. Prior to this Oscar worked as Director Equity Research, covering European listed life sciences companies at Kempen & Co. Oscar has advised on a wide variety of primary and secondary public offerings and M&A transactions across Europe. Before Kempen & Co he worked in various commercial roles in the industry, eventually in business development at Crucell. Oscar obtained his PhD in Pharmacology at TNO in the Netherlands and he holds an MSc degree in Biopharmaceutical Sciences from the University of Leiden.



Michael King

Nomura Code Securities

Michael joined Nomura Code Securities in 2003 from WestLB Panmure, having moved from SG Securities in 2000. He has over 13 years' experience as a healthcare analyst and specialises in medical technology companies, although previously his coverage has also included the biotechnology and pharmaceutical sectors. Prior to joining SG Securities in 1997, Michael spent 12 years in the medical technology industry, working for Amersham International (now GE Healthcare) and Pfizer Hospital Products,initially as a development scientist but mostly in international marketing. He graduated in 1985 with a degree in Biochemistry and Physiology from Southampton University.


Geraldine O'Keeffe

Life Sciences Partners

Geraldine, Partner, joined LSP as a Senior Investment Manager in 2008. Prior to joining LSP, she held the position of senior sell-side analyst at Fortis, where she focused exclusively on the global biotechnology industry. While at Fortis, she initiated and maintained coverage on a wide range of biotechnology companies and was actively involved in several IPOs. Before joining the investment community, Geraldine worked for Biotrin (now part of Diasorin) and was instrumental in gaining FDA approval for several diagnostic tests. She also lectured in Biomedical Sciences for several years at the Dublin Institute of Technology. Geraldine has a BSc Biochemistry/Microbiology from University College Cork, an MSc in Biotechnology from University College Galway, Ireland and conducted post-graduate research at the Max Planck Institute for Biophysical Chemistry and Oxford University. She is also a graduate of The Dublin School of Business.



Gareth Powell

Polar Capital Technology Trust PLC

Gareth joined Polar Capital in 2007 to set up the healthcare team. He has over 12 years' investment experience in the healthcare sector, with 10 years as a Portfolio Manager. He joined Framlington in 1999 becoming a portfolio manager on the Framlington Health fund. In 2002, he helped launch and then run the Framlington Biotech Fund. Gareth became a CFA charter holder in 2003. Gareth studied biochemistry at Oxford from 1995 to 1999 and during that time worked at Astellas, the Sir William Dunn School of Pathology, the Wolfson Institute for Biomedical Research and the Oxford Business School.



Ian Restall

Flathill Communications plc
Voting Panel Chairman

Throughout his career, Ian has been involved in the quoted growth companies sector. His early career was as a stockbroker, analyst, broadcaster and financial journalist in this area and, since founding The Design Portfolio Marketing Services in 1991, he has been active in helping many companies in this sector with their investor communication and corporate reporting requirements. Ian is also Chairman of Flathill Communications Group plc, President of The Design Portfolio Marketing Services Inc. and a member of the Investor Relations Society.


Nick Rodgers

IPSO Ventures plc

Nick is an experienced non-executive director and chairman with a background as a successful corporate financier. He has considerable experience of businesses in the healthcare, medical, biotechnology environmental and technology sectors.

Nick is Chairman of Oxford BioMedica plc, a leading gene-based biopharmaceutical company. Nick is also chairman of SEHTA Enterprises, the commercial arm of SEHTA, one of the largest health technology networking organisations in the UK. Until March 2013 Nick was the Chief Executive of Ipso Ventures plc, a creator and investor in early stage technology and healthcare businesses. As such he created eight businesses around university technology.



Jonathan Senior

Nomura Code Securities

Jonathan joined Nomura Code in 2007. Previously, Jonathan was part of the healthcare corporate finance team at Credit Suisse and then a research analyst on the number one ranked biotech team. During his time at Credit Suisse, Jonathan was involved with the IPOs of NicOx, GPC Biotech and Actelion, as well as transactions for PowderJect, Oxford GlycoSciences and Galen. After leaving Credit Suisse, Jonathan joined Evolution Securities as a research analyst, where he was involved in fundraisings for Oxford BioMedica and Entelos. Prior to joining Credit Suisse, Jonathan was a doctor, with his final job before leaving medicine as a senior house officer in cardiac surgery at the John Radcliffe hospital in Oxford. Jonathan studied medicine at Lincoln College, Oxford and also holds a BA in Physiological Sciences.


Julie Simmonds

Canaccord Genuity

Julie joined Canaccord Genuity when it acquired Collins Stewart in December 2010. Her research coverage focuses on small and mid-cap healthcare companies. Julie joined from Piper Jaffray where she spent five years as a Senior Analyst in the No. 1 Extel rated healthcare team. Her research coverage included both small and mid-cap UK healthcare companies, including medical devices, biotechnology and services, and large-cap European stocks. Prior to Collins Stewart Julie was with Nomura and previously Head of Life Sciences Research at Evolution Securities where she was an analyst from 1998 to 2004. Julie has a PhD in Microbiology from University of Kent at Canterbury. Prior to becoming an analyst Julie gained industrial experience in both Europe and the US.


Sachin Soni

Kempen & Co Merchant Bank

Sachin currently works as Director Equity Research (Life Sciences) at Kempen & Co where he is responsible for coverage of European healthcare/life sciences sector. He has over eight years of experience in the life sciences industry with an exposure to both private (venture capital) as well as public market investments and has been involved in multiple IPOs/secondary placements. Sachin started his career as a medical doctor where he worked as a general practitioner with the Indian Red Cross and Max Healthcare Hospital. He was ranked among top 0.1% students at All-India level in Physics and Chemistry and finished his degree in Medicine (MBBS) with honors in Pharmacology and Biochemistry from Seth G S Medical College & KEM Hospital, Mumbai, India. He holds a Master's in Business Administration with concentration in finance from Rotterdam School of Management, the Netherlands/Columbia Business School, US.



Melanie Toyne-Sewell

College Hill Life Sciences

Melanie is a specialist in financial and corporate communications for life science companies and heads up Financial PR for the life sciences team. Prior to College Hill, Melanie was Head of Healthcare at the Hogarth Partnership, a partner in the Financial Dynamics Life Sciences team and a Director of Merlin Financial. She has extensive experience of capital market transactions and corporate issues facing the pharma, biotech, medtech and healthcare sectors. Before entering the field of financial PR, Melanie was at Price Waterhouse where she qualified as a chartered accountant. She has a BA Hons in Biochemistry from Oxford University.


Annabel van Nieuwkerk

The Design Portfolio Marketing Services Limited

Annabel has worked at the Design Portfolio since 2011 where she specialises in corporate communications and investor relations, with a particular focus in annual reports and corporate websites. Prior to joining the Design Portfolio, Annabel spent three years working in commercial translation. She holds a degree in Law with French Law after studying at universities in both the UK and France and is currently completing her Master's degree in Applied Linguistics.